Please Note: This trial is no longer enrolling new participants
A Phase 2 Study of Neratinib with or without Fulvestrant in HER2-Positive, ER-Positive Metastatic Breast Cancer
| Protocol No. | 17-318 | Scope | National |
|---|---|---|---|
| Principal Investigator | Tarah Ballinger | Treatment Type | Treatment |
| Age Group | Adult | Phase | Phase II |
